Frazier Life Sciences Management’s Intellia Therapeutics NTLA Stock Holding History

Frazier Life Sciences Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-203,684	Closed	-$5.6M	–	54
2024 Q1	$5.6M	Hold	203,684	–	–	0.24%	44
2023 Q4	$6.21M	Hold	203,684	–	–	0.33%	44
2023 Q3	$6.44M	Hold	203,684	–	–	0.43%	39
2023 Q2	$8.31M	Hold	203,684	–	–	0.5%	36
2023 Q1	$7.59M	Hold	203,684	–	–	0.55%	36
2022 Q4	$7.11M	Hold	203,684	–	–	0.44%	36
2022 Q3	$11.4M	Hold	203,684	–	–	0.88%	27
2022 Q2	$10.5M	Hold	203,684	–	–	1%	27
2022 Q1	$14.8M	Buy	+203,684	New	+$17.3M	1.26%	28

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frazier Life Sciences Management's NTLA Position: Q2 2024 in Review

Frazier Life Sciences Management sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 203,684 shares — an estimated $5.6M sold.

Frazier Life Sciences Management first reported a position in NTLA in Q1 2022 and held it in 9 quarters. The position peaked at $14.8M in Q1 2022. 291 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.

Frazier Life Sciences Management reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
Frazier Life Sciences Management sold 203,684 Intellia Therapeutics shares in Q2 2024, an estimated $5.6M.
Frazier Life Sciences Management first reported a position in Intellia Therapeutics in Q1 2022 and held it in 9 quarters.
Frazier Life Sciences Management's Intellia Therapeutics position peaked at $14.8M in Q1 2022.
291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.

Based on Frazier Life Sciences Management's 13F filing for Q2 2024, filed 15 Aug 2024.